FMP
Feb 14, 2022(Last modified: Dec 19, 2023)
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares closed more than 7% higher on Friday, despite the company’s reported Q4 miss, with EPS coming in at $0.04, significantly below the Street estimate of $0.58. Revenue was $303.5 million, compared to the Street estimate of $320 million.
Analysts at Oppenheimer view the company’s guidance as optimistic, stating that they are encouraged by management's decision to provide first-time 2022 Ingrezza sales guidance, which is viewed as a signal of increased confidence and transparency in the business model. The company expects $1.25-$1.35 billion of Ingrezza net sales in 2022 representing 20% growth at the mid-point driven entirely by volume as net price/script of around $5,400 is expected to remain relatively constant.

In times of rising geopolitical tension or outright conflict, defense stocks often outperform the broader market as gove...

As Circle Internet (NYSE:CRCL) gains attention following its recent public listing, investors are increasingly scrutiniz...

LVMH Moët Hennessy Louis Vuitton (OTC:LVMUY) is a global leader in luxury goods, offering high-quality products across f...